Bausch + Lomb (B+L) recently received 510(k) clearance from the U.S. FDA for the therapeutic use of its Boston XO® and Boston XO2® gas permeable materials in treating several ocular surface diseases, including dry eye.
The Boston XO and Boston XO2 materials are reportedly use in a variety of custom specialty lenses, such as the Zenlens™ scleral lens from Alden Optical, a part of the Bausch + Lomb Specialty Vision Products business, and are also indicated for daily wear for the correction of refractive ametropia and the management of irregular corneal conditions.
The expanded indication reportedly allows scleral lenses manufactured with the Boston XO and Boston XO2 gas permeable materials to be used in the treatment of certain ocular surface conditions, including dry eye disease, limbal stem cell deficiencies, skin disorders with ocular surface manifestations, neurotrophic keratitis, corneal exposure that may benefit from the presence of an expanded tear reservoir, and the saline-hydrated environment inherent in a scleral lens design.
Click here to read the full press release.
Like what you read? Follow OptometryWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.